The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization

Shalev, Varda; Chodick, Gabriel; Goren, Iris; Silber, Haim; Kokia, Ehud; Heymann, Anthony

doi:10.1016/j.ijcard.2010.08.002

Cited by 128 publications

(106 citation statements)

References 18 publications

Supporting

Mentioning

100

Contrasting

Order By: Relevance

“…Since 1997, information on all members’ interactions (i.e., diagnoses, visits to primary and secondary care physicians, visits to outpatient clinics, hospitalizations, laboratory tests, and purchased and dispensed medications) have been downloaded daily to a central computerized database. In addition, MHS has developed and validated computerized registries of its patients suffering from major chronic diseases such as ischemic heart disease, oncological diseases, and diabetes [15, 16]. …”

Section: Subjectsmentioning

confidence: 99%

Efficacy of Liraglutide in a Real-Life Cohort

et al. 2014

View full text Add to dashboard Cite

IntroductionIn the Liraglutide Effect and Action in Diabetes (LEAD) randomized clinical trials (RCTs) assessing liraglutide in type 2 diabetes mellitus (T2DM), glycated hemoglobin (A1c) was reduced by 7–16 mmol/mol and weight by up to 3.4 kg. As real-life efficacy data on liraglutide is limited, the authors assessed clinical effects in a real-life cohort.MethodsIn this retrospective analysis from the Israeli Health Maintenance Organization Maccabi, of patients with T2DM, treated with liraglutide ≥6 months during 2011–2012, evaluations were performed at baseline and 6 months.ResultsInsulin-naïve patients (n = 1,101) treated with liraglutide with at least one A1c or weight measurement were identified. In 933 patients with an additional A1c value after 6 months, A1c decreased by 9 mmol/mol (p < 0.0001, 95% CI 7–11) from 72 mmol/mol. In patients receiving >2 oral antidiabetic drugs (OADs) prior to liraglutide treatment (80.7% patients), A1c decreased by 7 mmol/mol, and in those receiving ≤2 OADs, by 12 mmol/mol. In 453 patients with baseline data available, weight decreased by 2.55 kg (p < 0.0001); 173 patients (38.18%) achieved ≥1% A1c reduction. Furthermore, 91 patients (20.1%) achieved National Institute for Health and Care Excellence (NICE) criteria (decreased A1c ≥1%; weight ≥3%). Weight reduction was marginally correlated with A1c reduction.ConclusionsEvidence from real-life use of liraglutide demonstrated clinical effects similar to those demonstrated in RCTs.Electronic supplementary materialThe online version of this article (doi:10.1007/s13300-014-0062-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Subjectsmentioning

confidence: 99%

Efficacy of Liraglutide in a Real-Life Cohort

et al. 2014

View full text Add to dashboard Cite

show abstract

“…This score is highly correlated with SES measured by the Central Bureau of Statistics [9]. Data on chronic comorbid conditions were available through MHS' automated patient registries for cardiovascular diseases [10], diabetes [11], hypertension, and chronic kidney disease (CKD). Body mass index (BMI) was categorized using the World Health Organization's international classification [12].…”

Section: Methodsmentioning

confidence: 99%

Epidemiology of Amyotrophic Lateral Sclerosis: A Population-Based Study in Israel

et al. 2016

Self Cite

View full text Add to dashboard Cite

Background: Globally, the annual incidence and prevalence of amyotrophic lateral sclerosis (ALS) are estimated at 1.9 and 4.5 per 100,000 population, respectively. This study is aimed at describing the epidemiology of ALS in Israel in a real-world setting. Methods: A retrospective study was performed using the databases of Maccabi Healthcare Services (MHS), a 2-million-member health maintenance organization in Israel. The study included all MHS adults diagnosed with ALS between 1997 and 2013. In 2013, characteristics of ALS patients were compared to those of age-sex-matched patients without ALS. Survival after ALS diagnosis was assessed until death and until tracheostomy or death (follow-up through 2014). Results: In 2013 (n = 158), the prevalence of ALS was 8.1 per 100,000 population in MHS. In 1997-2013, a total of 375 ALS patients were diagnosed, corresponding to an average annual incidence of 1.8 per 100,000 population in MHS. The median survival from diagnosis to death was 3.5 years (95% CI 2.9-4.1), with approximately 28% surviving at least 10 years. Median tracheostomy-free survival was 2.5 years (95% CI 2.1-2.9). Conclusions: Results suggest that there is a relatively high prevalence of ALS in Israel. Further research is needed to investigate factors that may contribute to the survival of patients with ALS in Israel.

show abstract

“…History of hypertension, hyperlipidemia, heart disease (myocardial infarction, angina pectoris), lung and eye disease, and hypothyroidism are extracted from the MHS EPR and the Maccabi Cardiovascular register [27]. For simplicity, we do not present diagnoses that have not been associated with cognitive compromise in the literature or that have a frequency less than 10% in this sample.…”

Section: Methodsmentioning

confidence: 99%

The Israel Diabetes and Cognitive Decline (IDCD) study: Design and baseline characteristics

Beeri

Ravona‐Springer

Moshier

et al. 2014

Alzheimer's & Dementia

View full text Add to dashboard Cite

Background Type 2 diabetes (T2D) is associated with increased risk of dementia. The prospective longitudinal Israel Diabetes and Cognitive Decline study aims at identifying T2D-related characteristics associated with cognitive decline. Methods Subjects are population-based T2D 65+, initially cognitively intact. Medical conditions, blood examinations, and medication use data are since 1998; cognitive, functional, demographic, psychiatric, DNA, and inflammatory marker study assessments were conducted every 18 months. Because the duration of T2D reflects its chronicity and implications, we compared short (0–4.99 years), moderate (5–9.99), and long (10+) duration for the first 897 subjects. Results The long duration group used more T2D medications, had higher glucose, lower glomerular filtration rate, slower walking speed, and poorer cognitive functioning. Duration was not associated with most medical, blood, urine, and vital characteristics. Conclusions Tracking cognition, with face-to-face evaluations, exploiting 15 years of historical detailed computerized, easily accessible, and validated T2D-related characteristics may provide novel insights into T2D-related dementia.

show abstract

The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization

Cited by 128 publications

References 18 publications

Efficacy of Liraglutide in a Real-Life Cohort

Efficacy of Liraglutide in a Real-Life Cohort

Epidemiology of Amyotrophic Lateral Sclerosis: A Population-Based Study in Israel

The Israel Diabetes and Cognitive Decline (IDCD) study: Design and baseline characteristics

Contact Info

Product

Resources

About